Kazuaki Katakawa

Dr. Kazuaki Katakawa

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2019 in Organic Letters
Verified
Journal Article
Closed access
Takumi AbeTakumi Abe
Takumi Abe
YKYuta Kosaka
Yuta Kosaka
MAMiku Asano
Miku Asano
NHNatsuki Harasawa
Natsuki Harasawa
AMAkane Mishina
Akane Mishina
KYKoji Yamada
Koji Yamada

18 September 2019 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
MHMakoto Hashimoto
Makoto Hashimoto
TTTakaaki Taguchi
Takaaki Taguchi
KIKazuki Ishikawa
Kazuki Ishikawa
RMRyuichiro Mori
Ryuichiro Mori
AHAkari Hotta
Akari Hotta
KIKoji Ichinose
Koji Ichinose

7 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
HKHitoshi Kotani
Hitoshi Kotani
WHWei Han
Wei Han
YIYuichi Iida
Yuichi Iida
RTRyosuke Tanino
Ryosuke Tanino
KKKazuaki Katakawa
Kazuaki Katakawa
MHMAMORU HARADA
MAMORU HARADA
Background: Tyrosine kinase inhibitors (TKIs) inhibit receptor-mediated signals in cells. Axitinib is a TKI with high specificity for vascular endothelial growth factor receptors (VEGFRs). Aim: We determined whether axitinib could induce senescence in human cancer cells and be lysed by the senolytic drug ABT-263. Methods: Human lung and breast adenocarcinoma cell lines were used. These cells were cultured with axitinib or a multi-target TKI lenvatinib. The expression of β-galactosidase, VEGFRs, Ki-67, reactive oxygen species (ROS) of cancer cells, and their BrdU uptake were evaluated by flow cytometry. The mRNA expression of p21 and IL-8 was examined by quantitative PCR. The effects of TKIs on phosphorylation of Akt and Erk1/2, as downstream molecules of VEGFR signaling, were examined by immunoblot. The in vivo anti-cancer effect was examined using a xenograft mice model. Results: Axitinib, but not lenvatinib, induced cellular senescence (increased cell size and enhanced expression of β-galactosidase) in all adenocarcinoma cell lines. Axitinib-induced senescence was unrelated to the expression of VEGFRs on cancer cells. ROS were involved in axitinib-induced senescence. Axitinib-induced senescent lung adenocarcinoma A549 cells were drastically lysed by ABT-263. In A549-xenografted mice, combination therapy with axitinib and ABT-263 significantly suppressed tumor growth with the induction of apoptotic cancer cells.

4 May 2020 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
SSShunsuke Sueki
Shunsuke Sueki
MMMizuki Matsuyama
Mizuki Matsuyama
AWAzumi Watanabe
Azumi Watanabe
AKArata Kanemaki
Arata Kanemaki
KKKazuaki Katakawa
Kazuaki Katakawa
MAMasahiro Anada
Masahiro Anada

22 October 2021 in Molecules
Verified
Journal Article
Open access
PDF file
TKTakuya Kumamoto
Takuya Kumamoto
MKMika Kainuma
Mika Kainuma
ATAzusa Takahashi
Azusa Takahashi
YMYoshika Matsuo
Yoshika Matsuo
KKKazuaki Katakawa
Kazuaki Katakawa
KIKoji Ichinose
Koji Ichinose
In this article, we report the total synthesis of 6-deoxydihydrokalafungin (DDHK), a key biosynthetic intermediate of a dimeric benzoisochromanequinone antibiotic, actinorhodin (ACT), and its epimer, epi-DDHK. Tricyclic hemiacetal with 3-siloxyethyl group was subjected to Et3SiH reduction to establish the 1,3-cis stereochemistry in the benzoisochromane, and a subsequent oxidation/deprotection sequence then afforded epi-DDHK. A bicyclic acetal was subjected to AlH3 reduction to deliver the desired 1,3-trans isomer in an approximately 3:1 ratio, which was subjected to a similar sequence to that used for the 1,3-cis isomer that successfully afforded DDHK. A semisynthetic approach from (S)-DNPA, an isolable biosynthetic precursor of ACT, was also examined to afford DDHK and its epimer, which are identical to the synthetic products.

2 April 2025 in Acta Crystallographica Section F Structural Biology Communications
Verified
Journal Article
Open access
PDF file
DEDaichi Egawa
Daichi Egawa
HIHiroaki Ishida
Hiroaki Ishida
KKKazuaki Katakawa
Kazuaki Katakawa
Piperine has been investigated for a diverse array of biological effects, including a potential role in modulating peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor that plays a pivotal role in regulating lipid and glucose metabolism. This study conducted a comprehensive co-crystallographic analysis of the complex of piperine with the PPARγ ligand-binding domain (PPARγ-LBD), with the objective of elucidating the precise binding interactions of piperine. The co-crystal structure revealed that piperine binds within the ligand-binding pocket of PPARγ-LBD via hydrogen-bonding and hydrophobic interactions with residues of the ligand-binding site. Notably, in contrast to conventional full agonists, piperine does not directly stabilize helix H12. This could contribute to the comparatively weaker agonistic activity of piperine. The results of this study also suggest that piperine binding facilitates a role as a partial agonist or even an antagonist under certain physiological conditions. Collectively, these findings contribute to a greater understanding of the manner in which piperine modulates PPARγ function and its potential as a therapeutic candidate for the treatment of metabolic disorders. Given its natural origin and relatively minimal side-effect profile, piperine and its derivatives could be promising alternatives to synthetic PPARγ modulators such as thiazolidinediones, which have significant side effects.